NIAID will not move forward with the PAVE 100 HIV Vaccine Trial

After soliciting and considering broad input from the scientific and HIV advocacy communities, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has determined that it will not conduct the HIV vaccine study known as PAVE 100.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news135509645.html">NIAID will not move forward with the PAVE 100 HIV Vaccine Trial</a></p> <p>After soliciting and considering broad input from the scientific and HIV advocacy communities, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has determined that it will not conduct the HIV vaccine study known as PAVE 100. </p>